Back to Search

ROMAN PEREZ-SOLER, MD

MD

Medical Oncology Physician

NPI: 1316027808Individual

Specialties, Licenses & Credentials

Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

211726(NY)

Research & Publications (20)

Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer.
PMID 17671146·Clin Cancer Res·2007
6-review
Clinical research of EGFR inhibitors and related dermatologic toxicities.
PMID 18154213·Oncology (Williston Park)·2007
8-other
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
PMID 17239291·Clin Lung Cancer·2006
6-review
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
PMID 15638953·Clin Lung Cancer·2004
3-trial
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer.
PMID 15217965·Clin Cancer Res·2004
6-review
Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
PMID 11156254·Clin Cancer Res·2000
7-preclinical
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
PMID 19524318·Lung Cancer·2010
3-trial
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
PMID 19346126·Eur J Cancer·2009
7-preclinical
Skin toxicities associated with epidermal growth factor receptor inhibitors.
PMID 19452131·Target Oncol·2009
6-review
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
PMID 19130057·Cancer Chemother Pharmacol·2009
8-other
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
PMID 18339877·Cancer Res·2008
8-other
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
PMID 17762337·J Thorac Oncol·2007
8-other
EGFR inhibitor-mediated apoptosis in solid tumors.
PMID 18038764·J Exp Ther Oncol·2007
6-review
p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment.
PMID 17699870·Clin Cancer Res·2007
7-preclinical
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
PMID 18154212·Oncology (Williston Park)·2007
6-review
Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung.
PMID 17438100·Clin Cancer Res·2007
3-trial
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
PMID 17545550·Clin Cancer Res·2007
8-other
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
PMID 17671145·Clin Cancer Res·2007
7-preclinical
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
PMID 15746062·Clin Cancer Res·2005
4-observational
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
PMID 15908659·J Clin Oncol·2005
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
MMC - DEPT. OF ONCOLOGY, 111 EAST 210TH STREET
BRONX, NY 10467

Location

Practice Location

MMC - DEPT. OF ONCOLOGY, BRONX, NY
(718) 920-4001

Quick Facts

NPI
1316027808
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile